, cats (Honkavaara, Pypendop, & Ilkiw, 2017; Pypendop, Honkavaara, & Ilkiw, 2017a) and sheep (Bryant et al., 1998; Raekallio et al., 2010) .
Furthermore, MK-467 had no substantial effect on the intensity of sedation induced by medetomidine or dexmedetomidine Rolfe et al., 2012) .
Moreover, MK-467 increased the absorption rate and early-stage plasma concentrations of α 2 -agonists drugs when coadministered intramuscularly in cats (Pypendop, Honkavaara, & Ilkiw, 2017b) and dogs (Restitutti et al., 2017) , resulting in faster induction of sedation (Restitutti et al., 2017) .
Atipamezole (ATI) is a specific α 2 -adrenoceptor antagonist with an α 2 -vs. α 1 selectivity ratio of 8,500:1 (Virtanen, 1989) . It is effective in reversing medetomidine-induced sedation in sheep (Ko & McGrath, 1995; Ranheim, Arnemo, Stuen, & Horsberg, 2000) . However, relapses into sedation (i.e. resedation after an initial recovery) have been reported in some ruminant species (Ranheim, Arnemo, Ryeng, Soli, & Horsberg, 1999; Ranheim, Soli, Ryeng, Arnemo, & Horsberg, 1998; Ranheim et al., 1997) . In addition, ATI did not completely reverse medetomidine-induced hypoxaemia in sheep (Ko & McGrath, 1995; Talke et al., 2000) .
There are no previous reports on the concurrent intramuscular use of medetomidine with MK-467 followed by ATI in sheep. Therefore, we aimed to evaluate the effects of MK-467 and ATI on plasma drug concentrations, sedation and cardiopulmonary function in sheep receiving intramuscular medetomidine. We hypothesized that would increase the absorption of medetomidine when given simultaneously via the intramuscular route. Moreover, we speculated that MK-467 might potentiate the effects of ATI on haemodynamics when the sheep were exposed to both of these antagonists.
| MATERIALS AND METHODS

| Animals
Eight adult, healthy, nonpregnant female sheep (five crossbreed and three Texel) aged 1-5 years and weighing 44-78 kg were used in this study. The sheep were presumed healthy based on physical examination, complete blood counts and serum chemistry analysis.
The animals were kept in one group and fed hay and concentrate with free access to water. Six months before the start of the study, the right carotid arteries of the study animals were surgically elevated into a subcutaneous position under general anaesthesia using a technique modified from Tapio, Arguelles, Gracia-Calvo, and Raekallio (2017) . 
| Treatment groups
Each sheep received the following four treatments in a prospective, randomized, blinded, four-period crossover study with a minimum of 14 days between consecutive treatments: a) Medetomidine HCl (Dorbene 1 mg/ml; Syva Laboratories S.A., Spain) 30 μg/kg (Kästner et al., 2003) alone (MED) followed by saline 30 min later b) MED + MK-467 HCl (Vetcare Ltd., Finland) 300 μg/kg (MMK) in the same syringe followed by saline 30 min later c) MED followed by ATI HCl (Alzane 5 mg/ml; Syva Laboratories) 150 μg/kg 30 min later (MED + ATI) d) MMK followed by ATI HCl 150 μg/kg 30 min later (MMK + ATI).
All treatments were administered intramuscular into the semimembranosus muscle; the injection site (right and left) was alternated every other treatment. ATI or the corresponding volume of saline was administered in the contralateral muscle for the medetomidine-containing treatment. The MK-467 dose was derived from our previous study (Adam et al., 2016) , whereas ATI dosing and timing of administration were according to the manufacturer's recommendations (five times the dose of medetomidine after 30 min).
| Instrumentation
On the morning of the experiment day, the animals were weighed and kept upright in a padded sling such that their hooves did not touch the floor. The catheter insertion sites were aseptically prepared. Becton Dickinson, Sandy, Utah, USA), which were calibrated with a mercury manometer and zeroed to atmospheric pressure at the level of the manubrium.
| Study protocol
Heart rate (HR), CVP, systolic, diastolic and mean arterial pressures Ltd, Cambridge, UK) as previously described by Raekallio et al. (2010) .
Standard values of 10 g/dl haemoglobin and 140 mm of sodium were used and later corrected with measured values obtained from simultaneously taken arterial blood samples. These samples were anaerobically obtained (Pico50; Radiometer, Copenhagen, Denmark) via the arterial catheter at baseline and 10, 20, 40, 50, 60, 75 and 90 min and from the CVP catheter at baseline, 20, 40, 60, 75 and 90 min after treatment. The samples were placed in ice water for no longer than 10 min until analysed with a blood gas analyser (GEM Premier 4000, Bedford, Massachusetts, USA). Measurements were corrected to rectal temperature. Standard formulas (Boyd, McDonell, & Valliant, 1991) were used to calculate the following cardiopulmonary variables: cardiac index (CI), oxygen delivery (DO 2 ), arterial oxygen content (CaO 2 ) and systemic vascular resistance (SVR). A formula specific to sheep (Maginniss, Olszowka, & Reeves, 1986 ) was used for calculating arterial (SaO 2 ) and venous oxygen saturation (SvO 2 ).
Sedation was assessed using a visual scale from 0 to 10 (0 means no sedation; 10 means the sheep is deeply sedated and unresponsive to manipulation and hand clapping). Assessments were performed before drug administration and at intervals for up to 120 min thereafter by an investigator blinded to the treatments (MA). Resedation was defined as reduction in alertness and activity after the initial recovery.
For plasma drug concentrations, 6 ml of blood was collected from the arterial catheter at 20, 40, 50, 60, 75 and 90 min after treatment, kept in ice water and centrifuged at 3,000 g for 15 min. Plasma was stored at −20°C. At the end of each trial, all catheters were removed and meloxicam 0.5 mg/kg (Metacam 20 mg/ml; Boehringer Ingelheim, Germany) was administered intravenous.
| Drug analyses
The concentrations of dex-and levomedetomidine (reference standard: racemic medetomidine, TRC, Toronto, Ontario, Canada) in EDTA plasma were determined with high performance liquid chro- Sample preparation for the analysis of MK-467 and ATI was as follows: 50 μl plasma aliquots were treated with in-well protein precipitation on a Sirocco plate (Sirocco plate; Waters Co.) with 250 μl of internal standard solution in acetonitrile (ACN) (containing 100 ng/ml propranolol and 20 ng/ml chlorpromazine). After vigorous mixing for 5 min, the samples were centrifuged for 20 min at 4,000 RPM. (ng/mL) for MK-467 and ATI was 1-10 000.
| Statistical analysis
On the basis of previous studies in dogs and sheep (Raekallio et al., 2010) 
| RESULTS
Plasma concentrations of DEX and LEV at 20 min were threefold higher with MMK than with MED alone. When MED was administered alone, administration of ATI increased DEX and LEV plasma concentrations (Figure 1a-d) . On the other hand, the exposure to MK-467 (or DEX and LEV) was not significantly different between MMK and MMK + ATI.
The sedation scores are presented as median (range) in Table 1 . They were initially significantly higher with MMK than with MED. After 90 min, the scores were higher with MED than with MMK. After ATI, the scores decreased significantly in both treatments, but with MMK + ATI they were significantly lower than with MED + ATI. Resedation was observed in one animal after MMK + ATI and in four animals after MED + ATI.
Cardiopulmonary variables are presented as mean ± SD in Figure 2a -e and Tables 2 and 3 . No significant differences were PaO 2 initially decreased after all treatments. After MED alone, PaO 2 remained below baseline until the end of follow-up (Table 2) .
However, there were no differences between the treatments.
Moreover, RR (data not shown) did not differ significantly between treatments. DO 2 decreased significantly from baseline after both MED and MMK and remained reduced for the entire observation period.
This reduction was reversed with ATI (Table 3) .
| DISCUSSION
MK-467 increased the early plasma concentrations of both of medetomidine's stereoisomers (DEX and LEV) when coadministered intramuscular in the same syringe. This finding is consistent with recent reports in dogs (Restitutti et al., 2017) and cats (Pypendop et al., 2017b) . In sheep, we detected an almost threefold increase in DEX concentration in plasma by MK-467. Similarly, MK-467 after intramuscular administration approximately doubled the C max of DEX and reduced its T max in dogs (Restitutti et al., 2017) and cats (Pypendop et al., 2017b ). We did not take frequent enough samples to determine T max , as this was not the primary aim of our study. This accelerated absorption of medetomidine probably resulted from reversion of the medetomidine-induced local vasoconstriction by MK-467 when both drugs were mixed in the same syringe and thus administered to the same site, as suggested by Restitutti et al. (2017) . In the present study, the plasma concentrations of medetomidine's enantiomers were nearly identical. This is in contrast to the findings in dogs (Bennett, Salla, Raekallio, Scheinin, & Vainio, 2017; Bennett et al., 2016) , where DEX concentrations were significantly higher than those of LEV. In dogs, the clearance of LEV was significantly higher than that of DEX after administration of racemic medetomidine (Bennett et al., 2016) , whereas in sheep, the clearance of the enantiomers may be less different.
Reversal with ATI resulted in a remarkable increase in plasma DEX concentrations. For example, with MED, DEX plasma concentrations were increased threefold 10 min after ATI. However, in the presence of MK-467 (MMK + ATI), ATI did not increase plasma DEX concentrations. This difference between treatments could be attributed to the earlier achievement of C max with MMK as previously suggested.
T A B L E 2 Mean ± SD of blood gas analyses, rectal temperature (Temp) and haemoglobin (Hb) at baseline (BL) and at various time points in eight sheep after intramuscular administration of medetomidine HCl (30 μg/kg, MED) alone and combined with MK-467 HCl (300 μg/kg, MMK) in the same syringe, followed by intramuscular atipamezole (150 μg/kg, MED + ATI, MMK + ATI) or an equal volume of saline 30 min later However, the increase in plasma medetomidine concentration after ATI administration is a well-documented phenomenon in ruminants and was also reported after intravenous administration of the agonist (Ranheim et al., 1997 (Ranheim et al., , 1998 (Ranheim et al., , 1999 (Ranheim et al., , 2000 . For example, in sheep receiving intravenous ATI (200 μg/kg) 60 min after intravenous medetomidine (40 μg/kg), the maximum increase (approximately twofold to threefold) was detected 5 min after ATI administration; 25-45 min were necessary to regain the pre-ATI plasma medetomidine concentrations (Ranheim et al., 2000) . This phenomenon was not observed in other animals such as dogs (Salonen, Vuorilehto, Vainio, & Anttila, 1995) , horses (Knych, Steffey, & Stanley, 2012) , ponies (Dyer, Hsu, & Lloyd, 1987) or humans (Scheinin et al., 1998) . Ranheim et al. (2000) suggested that ATI might have displaced medetomidine from the highly perfused organs such as kidneys, lungs and liver, thus increasing its plasma concentration. The findings in the present study support this displacement hypothesis. In our study, ATI might have also increased the absorption of medetomidine from its injection site (due to improvement of global cardiovascular function), as after MED alone, plasma concentrations of DEX were stable throughout the follow-up period (suggesting equal absorption and elimination rates or a flip-flop phenomenon).
Sedation was induced more rapidly, and early sedation appeared to be more profound with treatments that included MK-467. On the other hand, from 90 min onwards, the level of sedation was higher with MED than MMK. These findings seemed to directly reflect the DEX plasma concentrations. Our results support the speculation that in sheep, there was no or limited receptor hysteresis and the degree of sedation directly represented (dex)medetomidine concentrations in plasma (Kästner et al., 2003; Muge, Chambers, & Livingston, 1996; Ranheim et al., 2000) , at least with the concentrations detected in our study. In some other ruminants, such as cattle and reindeer, plasma medetomidine concentrations appear to correlate less directly with its sedative effects (Ranheim et al., 1997 (Ranheim et al., , 1998 (Ranheim et al., , 1999 .
The sedation scores also declined faster after MMK + ATI than with MED + ATI. None of the sheep exhibited signs of overalertness after ATI. This is in contrast to a report by Ranheim et al. (2000) , where
sheep that received a similar dose ratio of ATI: medetomidine (5:1) became excited and exhibited muscle tremors. This could be due to the later administration of ATI (60 min) in that study, after considerable decay of the effects of medetomidine.
As our primary goal in this study was to evaluate ATI effects when used for reversal, we did not focus on monitoring the early period after treatment administration. However, we observed that MK-467 did not immediately antagonize the early cardiovascular impact of medetomidine. In our first sample taken at 20 min, the DEX:MK-467 plasma concentration ratio was approximately 1:38, which appeared insufficient to completely reverse the cardiovascular effects of MED.
For example, in isoflurane-anaesthetized dogs receiving medetomidine and MK-467 as an intravenous step infusion, the cardiovascular effects of MED were significantly attenuated at a plasma concentration ratio of 1:50 (Kaartinen et al., 2014 CaO 2 (mL/dL) MED 12.0 ± 1.3 10.4 ± 1.2 9.8 ± 0.7* 9.7 ± 0.8* 9.7 ± 0.7* 9.8 ± 0.7* MED + ATI 11.4 ± 1.3 9.7 ± 0.7* 10.8 ± 1.6 10.9 ± 1.2 § 11.6 ± 1.8 § 11.9 ± 2.8 MMK 11.4 ± 1.0 9.9 ± 0.8* 9.3 ± 0.7* 9.3 ± 0.8* 9.4 ± 0.6* 9.5 ± 0.6* MMK + ATI 11.5 ± 0.8 10.0 ± 0.7* 11.5 ± 0.9 # 12.4 ± 2.1 # 12.7 ± 2.0 # 12.5 ± 2.1 # DO 2 (mL/min/kg) MED 11.1 ± 3.6 6.7 ± 0.8* 6.4 ± 0.5* 6.7 ± 0.7* 6.2 ± 0.8* 6.2 ± 0.9* MED + ATI 10.1 ± 1.8 6.5 ± 1.7* 8.7 ± 3.0 § 9.0 ± 3.1 9.9 ± 3.0 § 10.0 ± 2.9 § MMK 10.4 ± 1.4 7.8 ± 2.1 7.4 ± 1.5* 6.5 ± 0.9* 7.0 ± 1.3* 7.5 ± 1.9* MMK + ATI 9.4 ± 1.0 8.2 ± 1.6 10.5 ± 2.3 baseline values. However, MAP was significantly decreased and was also lower than with MED. This could be partially attributed to the central sympatholytic effects of MED, as MK-467 alone did not significantly alter MAP in dogs or cats (Honkavaara et al., 2017; Pypendop et al., 2017a (Rioja, Kerr, Enouri, & McDonell, 2008) but not in sheep (Talke et al., 2000) and goats (Carroll et al., 2005) treated with medetomidine.
Arterial hypoxaemia is a common adverse effect associated with use of all α 2 -agonists in sheep. The dose, route of administration and individual sensitivity appear to determine the degree of effect on PaO 2 (Bryant et al., 1996; Dyck, Maze, Haack, Vuorilehto, & Shafer, 1993; Kästner et al., 2007; Talke et al., 2000) . In our study, PaO 2 initially (at 10 min) decreased after all treatments, although none of the sheep became hypoxaemic (PaO 2 < 60 mmHg). That MK-467 did not seem to significantly improve PaO 2 may be related to its slow absorption or may be this population of sheep was not sensitive to medetomidineinduced hypoxaemia, at least after intramuscular administration. DO 2 is a product of CaO 2 and CO. In our study, the sustained decrease in DO 2 with MMK was probably attributed more to the decrease in CaO 2 , which reflects changes both in Hb concentration and PaO 2 .
Thus, as Hb concentrations (and PaO 2 ) were restored after ATI, both CaO 2 and DO 2 increased. Nevertheless, at no time point did MED or MED + ATI perform better than the treatments that included MK-467.
In the current study, medetomidine concentrations in blood were much below those reported to induce relevant bias with LiDCO sensors in vitro (Ambrisko, Kabes, & Moens, 2013) . On the other hand, ATI does not markedly interfere with the performance of LiDCO electrodes (Ambrisko et al., 2013) . Currently, there are no available data about the possible effect of MK-467 on LiDCO sensor voltage, and it is unclear whether it affected the accuracy of the readings. In general, we believe that our CO measurements and consequently CI were minimally affected by the used drugs.
Last, all of the animals in the present study were intact females. As there is no published information on possible gender effects on the responses to α 2 -adrenoceptor agonists and antagonists in animals, further investigation characterising the impact of sex and/or hormonal status may be warranted.
In conclusion, intramuscular coadministration of the peripheral 
